A Confirmatory Study Confirming Performance of a New Intermittent Catheter

NCT ID: NCT05485935

Last Updated: 2025-03-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 73 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-20
• Study Completion Date: 2023-01-03

Brief Summary

A multi-centre, randomized, controlled crossover design. The total study duration for the individual subject was approximately 9 weeks. The study consisted of four study visits (V0-V3) and two 4-week test periods at home (T1 and T2). Visit 0 and 1 was performed on the same day if subjects allowed.

One population included all enrolled subjects who took part in the two test periods in a home setting only (T1 and T2). This constituted the Full Analysis Set (FAS) 1 (N=73)where only endpoints related to dipstick hematuria, catheter perception and quality of life were assessed.

A subset of subjects from the FAS1 also took part in two clinic visits (V2 and V3) where endpoints related to bladder emptying and discomfort were assessed. One visit took place in between the two test periods at home (V2) and the other visit took place after the last test period at home (V3) which was also the termination visit. This subset is termed the FAS 2 (N=49).

Detailed Description

This investigation was a multi-centre, randomized, controlled crossover study including 73 male clean intermittent catheterization (CIC) users.

The study consisted of four study visits (V0-V3) and two 4-week test periods at home (T1 and T2). Visit 0 and 1 were performed on the same day if participants allowed. Visit 0 included the screening-, inclusion-, and randomization phase of participants and at visit 1, participants performed a self-catheterization with the device according to their respective randomization scheme. This was followed by a dipstick test for hematuria. This constituted the Full Analysis Set (FAS) 1, consisting of 73 participants.

In the two 4-week test periods (T1 and T2, respectively) the participants catheterized at home with the specified catheter according to their randomization scheme. Both 4-week periods started with a 2-week run-in period followed by a 2-week period during which a dipstick test for hematuria was performed daily.

For Visit 2 and 3, a sub-group of participants was invited for a clinical test visit during which participants were catheterized with the same device applied during the preceding home-test period. First a healthcare professional (HCP)-led catheterization was performed followed by a self-catheterization, and endpoints related to bladder emptying (residual urine and number of urinary flow-stop episodes) were measured. After each catheterization, any residual urine left in the bladder was measured with a bladder scanner and hematuria was assessed with a dip-stick test. After the self-catheterization process, subjects at clinic visit V2 and V3 completed a questionnaire related to discomfort.This constituted the Full Analysis Set (FAS) 2, consisting of 49 participants.

All participants completed a perception questionnaire and a HRQoL questionnaire associated with the catheter during the last two weeks of the home test period. For participants not part of clinic visits V2 and V3, a nurse assisted with the questionnaires after each home-test period during a remote home visit. Thereafter, all participants were introduced to the second device to be tested for the next home-test period.

After the second home-test period, the study was terminated with a test visit 3 (V3), either in the clinic (for the subset group, FAS2) or a home visit by the nurse (the FAS1 group).

Conditions

Urinary Retention

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Investigational device - intermittent catheter with micro-hole zone

Single-use, sterile, hydrophilic coated intermittent male catheter. The external diameter is measured in millimeters (Charrière scale: Ch, CH) and the sizes available were CH12 and CH14 with a flexible tip and a micro-hole zone for urinary drainage.

Group Type: EXPERIMENTAL

Investigational device - intermittent catheter with micro-hole zone

Intervention Type: DEVICE

Intermittent male catheter with micro-hole zone for urinary drainage

Comparator device - standard intermittent catheter

Single-use, sterile, hydrophilic coated intermittent male catheters (sizes CH12 and CH14) with sleeves: SpeediCath Flex, VaPro, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.

Group Type: ACTIVE_COMPARATOR

Comparator - standard intermittent catheter

Intervention Type: DEVICE

SpeediCath Flex, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.

Interventions

Investigational device - intermittent catheter with micro-hole zone

Intermittent male catheter with micro-hole zone for urinary drainage

Intervention Type: DEVICE

Comparator - standard intermittent catheter

SpeediCath Flex, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Male

2. Was at least 18 years of age and had full legal capacity

3. Had given written informed consent

4. Had signed letter of authority (only DK)

5. Had used clean intermittent self-catheterization (CISC) for at least the last 3 months

6. Had used intermittent catheterization as the only bladder emptying method for at least the last 3 months

7. Self-catheterized using Coloplast SpeediCath Flex or Hollister VaPro catheters, CH12 or CH14, for at least 3 months prior to inclusion

8. Had the ability (assessed by investigator) and willingness to adhere to a 2-month study period

Exclusion Criteria

1. Participation in any other clinical study during this investigation

2. Previous participation in the study

3. Symptoms of urinary tract infection as judged by the investigator (rescheduling allowed within recruitment period for LPI)

4. Individuals with history, suspected or showing signs of producing urine with excessive amount of mucus or large/clustered sediments or debris

5. Any known allergies towards ingredients in the investigational device

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Coloplast A/S

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nikesh thiruchelvam, Dr

Role: STUDY_CHAIR

NHS Foundation Trust

Locations

Sanos Clinic

Gandrup, North Denmark, Denmark

Rigshospitalet

Copenhagen, , Denmark

Hopital Claude Huriez

Lille, , France

Hôpital Tenon

Paris, , France

Artimed

Kassel, , Germany

Illingworth Research Group

Macclesfield, Cheshire, United Kingdom

Countries

Denmark; France; Germany; United Kingdom

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

CP334

Identifier Type: -

Identifier Source: org_study_id